Role of Hepatitis B Surface Antibodies in Risk for Hepatitis B Virus Reactivation During Anti-Tumor Necrosis Factor Therapy.

Abstract

An estimated 250 million people are chronically infected with hepatitis B virus (HBV), with more than 800,000 deaths related to HBV.1 Although the prevalence of HBV has been decreasing, reactivation remains a cause for concern.2 Reactivation is defined by the resurgence of HBV DNA and/or HBV surface antigen (HBsAg) seroreversion in patients with resolved HBV or an increase in HBV viral load in chronic hepatitis.3 Anti-tumor necrosis factor (TNF) therapies have been shown to place patients at a risk for HBV reactivation.4.

• Authors: Shiva Poola, Marykate Kratzer, Sirish Sanaka, Kerry Sewell, Hans L Tillmann
• Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (Clin Gastroenterol Hepatol) Vol. 21 Issue 4 Pg. 1103-1104.e3 (04 2023) ISSN: 1542-7714 [Electronic] United States
• PMID: 35189389 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 AGA Institute. All rights reserved.

Chemical References

• Hepatitis B Antibodies
• Hepatitis B Surface Antigens
• DNA, Viral
• Antiviral Agents

Topics

• Humans
• Hepatitis B virus
• Hepatitis B Antibodies
• Hepatitis B Surface Antigens
• Hepatitis B (drug therapy)
• Necrosis
• Virus Activation
• DNA, Viral
• Antiviral Agents (therapeutic use)